Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Copyright © 2014 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 155(2014), 2 vom: 04. Dez., Seite 160-75
1. Verfasser: Wang, Yao (VerfasserIn)
Weitere Verfasser: Zhang, Wen-ying, Han, Qing-wang, Liu, Yang, Dai, Han-ren, Guo, Ye-lei, Bo, Jian, Fan, Hui, Zhang, Yan, Zhang, Ya-jing, Chen, Mei-xia, Feng, Kai-chao, Wang, Quan-shun, Fu, Xiao-bing, Han, Wei-dong
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Anti-CD20 chimeric antigen receptor (CAR) T cells; Delayed toxicities Diffuse large B-cell lymphoma (DLBCL); Refractory advanced; Antigens, CD20 Receptors, Antigen, T-Cell Recombinant Fusion Proteins Tumor Necrosis Factor Receptor Superfamily, Member 9
Beschreibung
Zusammenfassung:Copyright © 2014 Elsevier Inc. All rights reserved.
We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3ζ moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL). Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-month durable and ongoing complete remission by cell infusion only, and another attained a 6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for clinical efficacy, three of which attained 3- to 6-month tumor regression. Delayed toxicities related to cell infusion are directly correlated to tumor burden and tumor-harboring sites, and mainly included cytokine release symptoms, tumor lysis symptoms, massive hemorrhage of the alimentary tract and aggressive intrapulmonary inflammation surrounding extranodal lesions. These results show firstly that anti-CD20 CART cells can cause prolonged tumor regression in combination with debulking conditioning regimens for advanced DLBCL. This study is registered at www.clinicaltrials.gov as NCT01735604
Beschreibung:Date Completed 19.02.2015
Date Revised 08.01.2021
published: Print-Electronic
ClinicalTrials.gov: NCT01735604
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2014.10.002